Psychological and cognitive determinants of vision function in age-related macular degeneration

Archives of Ophthalmology

Volumn 129, Issue 7, 2011, Pages 885-890

  Rovner, Barry W ^a   Casten, Robin J ^a   Massof, Robert W ^b   Leiby, Benjamin E ^c   Tasman, William S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Wills Eye Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; COGNITION; COPING BEHAVIOR; DEPRESSION; FEMALE; HEALTH; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; OUTPATIENT; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOSOCIAL CARE; RETINA MACULA AGE RELATED DEGENERATION; SELF REPORT; VISION; VISUAL ACUITY;

ADAPTATION, PSYCHOLOGICAL; AGED, 80 AND OVER; COGNITION DISORDERS; DEPRESSIVE DISORDER; DISABILITY EVALUATION; FEMALE; HUMANS; INTELLIGENCE TESTS; MACULAR DEGENERATION; MALE; NATIONAL EYE INSTITUTE (U.S.); QUESTIONNAIRES; SICKNESS IMPACT PROFILE; UNITED STATES; VISION DISORDERS; VISUAL ACUITY;

EID: 79960190528     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.146     Document Type: Article

References (44)

1. Congdon N, O'Colmain B, Klaver CC, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485. (Pubitemid 38456282)
2. Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J; Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009;127(4):533-540.
3. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am. 2006;19(3):361-372. (Pubitemid 44279358)
4. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355 (14):1419-1431. (Pubitemid 44511557)
5. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl JMed. 2006;355(14):1432-1444. (Pubitemid 44511558)
6. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR; MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460-1469. (Pubitemid 350106676)
7. Bressler SB. Anti-VEGF therapy impact on daily life: what we have learned from quality-of-life research. Ophthalmol Times. 2006;31:10-12.
8. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD; National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050-1058. (Pubitemid 32652197)
9. Mangione CM, Berry S, Spritzer K, et al. Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol. 1998;116(2):227-233.
10. Massof RW, Fletcher DC. Evaluation of the NEI visual functioning questionnaire as an interval measure of visual ability in low vision. Vision Res. 2001;41(3):397-413. (Pubitemid 32112668)
11. Owsley C, McGwin G Jr. Depression and the 25-item National Eye Institute Visual Function Questionnaire in older adults. Ophthalmology. 2004;111(12):2259-2264. (Pubitemid 39575597)
12. Miskala PH, Bressler NM, Meinert CL. Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. Arch Ophthalmol. 2004;122(5):758-766. (Pubitemid 38596257)
13. Cuijpers P, van Straten A, Warmerdam L. Problem solving therapies for depression: a meta-analysis. Eur Psychiatry. 2007;22(1):9-15. (Pubitemid 46162183)
14. Borkovec TD, Newman MG, Pincus AL, Lytle R. A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult Clin Psychol. 2002;70(2):288-298. (Pubitemid 34274873)
15. Reischies FM, Geiselmann B. Age-related cognitive decline and vision impairment affecting the detection of dementia syndrome in old age. Br J Psychiatry. 1997; 171:449-451. (Pubitemid 27475843)
16. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197-203.
17. Lawton MP, Moss M, Fulcomer M, Kleban MH. A research and service oriented multilevel assessment instrument. J Gerontol. 1982;37(1):91-99. (Pubitemid 12215937)
18. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. (Pubitemid 32823891)
19. Lucas JA, Ivnik RJ, Smith GE, et al. Mayo's Older African Americans Normative Studies: norms for Boston Naming Test, Controlled Oral Word Association, Category Fluency, Animal Naming, Token Test, Wrat-3 Reading, Trail Making Test, Stroop Test, and Judgment of Line Orientation. Clin Neuropsychol. 2005;19(2):243-269.
20. Stelmack JA, Stelmack TR, Massof RW.Measuring low-vision rehabilitation outcomes with the NEI VFQ-25. Invest Ophthalmol Vis Sci. 2002;43(9):2859-2868. (Pubitemid 34977033)
21. Ryan B, Court H, Margrain TH. Measuring low vision service outcomes: Rasch analysis of the seven-item National Eye Institute Visual Function Questionnaire. Optom Vis Sci. 2008;85(2):112-121. (Pubitemid 351315438)
22. Marella M, Pesudovs K, Keeffe JE, O'Connor PM, Rees G, Lamoureux EL. The psychometric validity of the NEI VFQ-25 for use in a low-vision population. Invest Ophthalmol Vis Sci. 2010;51(6):2878-2884.
23. Pesudovs K, Gothwal VK, Wright T, Lamoureux EL. Remediating serious flaws in the National Eye Institute Visual Function Questionnaire. J Cataract Refract Surg. 2010;36(5):718-732.
24. Heckhausen J, Wrosch C, Schulz R. Amotivational theory of life-span development. Psychol Rev. 2010;117(1):32-60.
25. Wahl HW, Schilling O, Becker S. Age-related macular degeneration and change in psychological control: role of time since diagnosis and functional ability. J Gerontol B Psychol Sci Soc Sci. 2007;62(2):90-97.
26. Brennan M, Boerner K, Reinhardt JP, Horowitz A. Applying the life-span theory of control in adjustment to chronic illness: the development of the Vision- Specific OPS Scale. Poster presented at: Annual Meeting of the Gerontological Society of America; November 2004; Washington, DC.
27. Moustaki I. A general class of latent variable models for ordinal manifest variables with covariate effects on the manifest and latent variables. Br J Math Stat Psychol. 2003;56(pt 2):337-357. (Pubitemid 37434229)
28. Skrondal A, Rabe-Hesketh S. Generalized Latent Variable Modeling: Multilevel, Longitudinal and Structural Equation Models. Boca Raton, FL: Chapman Hall/CRC; 2004.
29. Muthén LK, Muthén BO. Mplus User's Guide. 6th ed. Los Angeles, CA: Muthén & Muthén; 2010.
30. Rees G, Tee HW, Marella M, Fenwick E, Dirani M, Lamoureux EL. Vision-specific distress and depressive symptoms in people with vision impairment. Invest Ophthalmol Vis Sci. 2010;51(6):2891-2896.
31. Submacular Surgery Trials Research Group. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ): SST report number 19. Ophthalmic Epidemiol. 2007;14 (4):205-215.
32. Lindblad AS, Clemons TE. Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS report No. 14. Arch Ophthalmol. 2005;123(9):1207-1214. (Pubitemid 41316735)
33. Miskala PH, Hawkins BS, Mangione CM, et al; Submacular Surgery Trials Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization - SST report No. 1. Arch Ophthalmol. 2003;121(4):531-539. (Pubitemid 36427640)
34. Massof RW. A systems model for low vision rehabilitation, II: measurement of vision disabilities. Optom Vis Sci. 1998;75(5):349-373. (Pubitemid 28268555)
35. Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol. 2002;120(8):1041-1044. (Pubitemid 34856071)
36. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116(4):514-520. (Pubitemid 28169754)
37. Horowitz A, Reinhardt JP, Kennedy GJ. Major and subthreshold depression among older adults seeking vision rehabilitation services. Am J Geriatr Psychiatry. 2005; 13(3):180-187. (Pubitemid 41031085)
38. Weintraub S. Neuropsychological assessment of mental state. In: Mesulam M-M, ed. Principles of Behavioral and Cognitive Neurology. 2nd ed. Oxford, England: Oxford University Press; 2000:121-173.
39. Ardila A. On the evolutionary origins of executive functions. Brain Cogn. 2008;68 (1):92-99.
40. Whitson HE, Cousins SW, Burchett BM, Hybels CF, Pieper CF, Cohen HJ. The combined effect of visual impairment and cognitive impairment on disability in older people. J Am Geriatr Soc. 2007;55(6):885-891. (Pubitemid 47011027)
41. Baker ML, Wang JJ, Rogers S, et al. Early age-related macular degeneration, cognitive function, and dementia: the Cardiovascular Health Study. Arch Ophthalmol. 2009;127(5):667-673.
42. Rovner BW, Casten RJ, Leiby BE, Tasman WS. Activity loss is associated with cognitive decline in age-related macular degeneration. Alzheimers Dement. 2009;5(1):12-17.
43. Clemons TE, Rankin MW, McBee WL; Age-Related Eye Disease Study Research Group. Cognitive impairment in the Age-Related Eye Disease Study: AREDS report No. 16. Arch Ophthalmol. 2006;124(4):537-543.
44. Campbell RJ, Bronskill SE, Bell CM, Paterson JM, Whitehead M, Gill SS. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a populationbased analysis. Arch Ophthalmol. 2010;128(3):359-362.